Sacituzumab (anti-Trop-2)

Sacituzumab (anti-Trop-2) is a fully humanized IgG1 kappa monoclonal antibody that targeting binds Trop-2 protein found on the surface of cancer cells. It can be used in the synthesis of an antibody-drug conjugate (ADC) through conjugate Sacituzumab with topoisomerase inhibitor drug (SN38). The ADC Sacituzumab govitecan, sold under the brand name Trodelvy, used primarily for the treatment of certain types of cancer, including metastatic triple-negative breast cancer and metastatic urothelial cancer. This biosimilar antibody is used for research only.

Product Details
Species Reactivity	Human
Host/Isotype	Human IgG1
Class	Monoclonal
Type	Recombinant Antibody
Immunogen	Human Trop2
Clone	Sacituzumab biosimilar
Conjugate	Unconjugated
Purity	99%
Protein Concentration	1mg/ml
Storage Condition	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Storage Buffer	100mM Pro-Ac, 20mM Arg-Ac, pH 5.0